Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chachoua

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimenH Hochster, L Liebes, J Speyer, et al.
Journal of the National Cancer Institute|May 6, 1992
Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanomaL Liebes, C M Walsh, A Chachoua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic studyH Hochster, L Liebes, J Speyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicityC Wasserheit, A Frazein, R Oratz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignanciesM A Rosenthal, D Dennis, L Liebes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancerY J Ko, E J Small, F Kabbinavar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton, J P Eder, A C Pavlick, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimenH Hochster, L Liebes, J Speyer, et al.
Journal of the National Cancer Institute|May 6, 1992
Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanomaL Liebes, C M Walsh, A Chachoua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic studyH Hochster, L Liebes, J Speyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicityC Wasserheit, A Frazein, R Oratz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 28, 1998
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignanciesM A Rosenthal, D Dennis, L Liebes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancerY J Ko, E J Small, F Kabbinavar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycleA L Hamilton, J P Eder, A C Pavlick, et al.
Pageof 3